All news
News
Press
Publications
Dr. Ashiq H. Khan joins Molecular Health’s Pharma & Biotech segment as Vice President (In Silico Biomedicine).
The molecular characterization of patient tumors provides a rational and highly promising approach for guiding oncologists in treatment decision-making. Notwithstanding, genomic medicine still remains…
Heidelberg, Germany – May 31, 2019 – Molecular Health (MH), a leading company in the field of data science for precision medicine, today announced that the Company…
Heidelberg, Germany – Tuesday, May 7, 2019–Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of…
Molecular Health is sponsor and exhibitor at the 103rd Annual Meeting of the German Society of Pathology in Frankfurt.
It holds a lunch symposium on…
Adverse Event Circumstances and the Case of Drug Interactions.
Molecular Health Guide (MH Guide) shortlisted forthe German Digital Health Award 2019
• Novartis and Sandoz/Hexal nominate seven out of 119 submissions
• MH Guide enables…
Peter Schotland, Rebecca Racz, David Jackson, Robert Levin, David G. Strauss and Keith Burkhart
• Molecular Health Predict enables highly accurate estimates of clinical trial success probabilities
• Exclusive license for the financial industry granted to DATEN CAPITAL
• Molecular Health to…
Dr. Ashiq H. Khan joins Molecular Health’s Pharma & Biotech segment as Vice President (In Silico Biomedicine).
Molecular Health is sponsor and exhibitor at the 103rd Annual Meeting of the German Society of Pathology in Frankfurt.
It holds a lunch symposium on…
Benefit from our software-aided interpretations for personalized cancer treatment
• Latest and comprehensive clinical evidence gathered from top publications/databases…
Clinical trials can fail to detect rare adverse events (AEs). We assessed the ability of pharmacological target adverse‐event (TAE) profiles to predict AEs on US Food…
• MH Mendel combines the most relevant information for the diagnosis of hereditary diseases
• MH Mendel helps patients and supports physicians through most modern and comprehensive…
Molecular Health to pursue drug repurposing in tuberculosis treatment and perinatal complications
Molecular Health receives grant from Bill & Melinda Gates Foundation
Heidelberg, Germany/Boston, MA, May 16, 2018…
Heidelberg, Walldorf, 6 April 2018. From 26 March 2018, SAP will provide access to the “Corporate Oncology Program for Employees” (COPE®), developed by Molecular Health and offered…
Case reports suggest an association between second-generation antipsychotics (SGAs) and serotonin syndrome (SS). The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) was…
MH Guide makes interpreting and reporting of clinical variants faster, easier and more accurate. It contextualizes patient-specific molecular data against global biomolecular knowledge and…
Heidelberg, Germany – May 31, 2019 – Molecular Health (MH), a leading company in the field of data science for precision medicine, today announced that the Company…
Heidelberg, Germany – Tuesday, May 7, 2019–Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of…
Molecular Health Guide (MH Guide) shortlisted forthe German Digital Health Award 2019
• Novartis and Sandoz/Hexal nominate seven out of 119 submissions
• MH Guide enables…
• Molecular Health Predict enables highly accurate estimates of clinical trial success probabilities
• Exclusive license for the financial industry granted to DATEN CAPITAL
• Molecular Health to…
Heidelberg, Germany and Boston, USA – July 3, 2018 – Molecular Health (MH), a leading biomedical company that is transforming molecular data into clinically actionable information for efficient and safer…
New features for intuitive biomarker classification and improved usability
Heidelberg, Germany and Boston, USA – June 1, 2018 – Molecular Health (MH), a leading company in the…
Molecular Health receives grant from Bill & Melinda Gates Foundation
Heidelberg, Germany/Boston, MA, May 16, 2018. Molecular Health announces it was awarded a grant from…
As it gains a foothold in international markets, Molecular Health will be demonstrating its latest product developments at the Arab Health Exhibition and Congress in…
New features for intuitive biomarker classification and improved usability
Heidelberg, Germany and Boston, USA – June 1, 2018 – Molecular Health (MH), a leading company in the field of…
The molecular characterization of patient tumors provides a rational and highly promising approach for guiding oncologists in treatment decision-making. Notwithstanding, genomic medicine still remains…
Adverse Event Circumstances and the Case of Drug Interactions.
Peter Schotland, Rebecca Racz, David Jackson, Robert Levin, David G. Strauss and Keith Burkhart
We present a novel approach for the molecular transformation and analysis of patient clinical phenotypes.
Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data.
Racz, Soldatos, Jackson, Burkhart. Clin Transl Sci (2018) 00, 1–8; doi:10.1111/cts.12543
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with an extremely poor prognosis, predominantly as a result of chemotherapy resistance and numerous somatic mutations.
Bohnert, Vivas, Jansen https://doi.org/10.1371/journal.pone.0186175
Rieber, Bohnert, Ziehm, Jansen Bioinformatics. 2017 Sep 15;33(18):2791-2798
To find out more, you can call our customer service or send us an e-mail. We would be delighted to provide you with more information or answer your questions.
